NNVC

NanoViricides, Inc. AMEX Listed Oct 26, 2005

Healthcare ·Biotechnology ·US · nanoviricides.com

$1.41

Mkt Cap $25.2M

52w Low $0.85 40.6% of range 52w High $2.23

50d MA $1.10 200d MA $1.29

P/E (TTM) -2.1x

EV/EBITDA -2.2x

P/B 2.6x

Debt/Equity 0.0x

ROE -87.2%

P/FCF -2.5x

RSI (14) —

ATR (14) —

Beta 1.30

50d MA $1.10

200d MA $1.29

Avg Volume 252.2K

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

SIC Code

2834

CIK (SEC)

1379006

Phone

203 937 6137

1 Controls Drive · Shelton, CT 06484 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 17, 2026	AMC	-0.14	-0.11	+21.4%	1.03	-1.0%	+1.0%	-2.9%	+1.0%	-1.0%	+3.0%	—
Nov 14, 2025	AMC	-0.18	-0.10	+44.4%	1.42	+5.6%	+2.8%	-5.5%	+2.2%	-12.1%	+2.4%	—
Sep 29, 2025	AMC	-0.20	-0.13	+35.0%	1.42	-1.4%	+0.7%	+0.7%	-0.7%	-3.5%	+5.1%	—
May 15, 2025	AMC	-0.19	-0.14	+26.3%	1.31	+9.2%	+7.6%	+3.5%	+6.8%	-6.4%	+1.4%	—
Feb 14, 2025	AMC	-0.18	-0.14	+22.2%	1.35	+2.2%	+0.0%	+1.5%	+5.8%	+3.4%	-5.3%	—
Nov 14, 2024	AMC	-0.17	-0.23	-35.3%	1.34	+4.5%	-8.2%	+4.9%	+6.2%	-2.9%	-3.8%	—
Sep 27, 2024	AMC	-0.20	-0.19	+5.0%	1.45	-4.1%	+3.4%	-2.7%	+2.1%	-5.4%	+4.3%	—
May 15, 2024	AMC	-0.19	-0.16	+15.8%	1.80	+5.0%	+23.9%	-7.2%	+2.4%	+2.8%	+4.1%	—
Feb 14, 2024	AMC	-0.19	-0.18	+5.3%	1.17	+2.6%	+1.7%	+3.4%	+0.8%	+0.0%	+2.4%	—
Nov 14, 2023	AMC	-0.17	-0.17	+0.0%	1.34	+3.0%	-9.7%	-6.0%	-3.3%	+3.6%	-4.4%	—
Oct 13, 2023	AMC	-0.17	-0.31	-82.4%	1.21	+0.0%	-3.3%	+0.0%	+3.4%	-5.0%	+0.0%	—
May 15, 2023	AMC	-0.17	-0.15	+11.8%	1.12	+0.0%	-5.4%	+3.8%	+1.7%	+4.5%	-2.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 7	EF Hutton	Maintains	Buy → Buy	—	$1.40	$1.60	+14.3%	+20.0%	+20.8%	-9.9%	+3.3%	-3.7%
Feb 16	EF Hutton	Maintains	Buy → Buy	—	$1.19	$1.22	+2.5%	+3.4%	+0.8%	+0.0%	+2.4%	+4.7%
Apr 18	EF Hutton	Maintains	Buy → Buy	—	$1.42	$1.48	+4.0%	-0.9%	-1.7%	-3.4%	+2.6%	-6.9%

Data updated apr 26, 2026 3:26pm · Source: massive.com